Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.51B P/E 6.64 EPS this Y -5.10% Ern Qtrly Grth -
Income 54.7M Forward P/E 3.65 EPS next Y 0.40% 50D Avg Chg 6.00%
Sales 15.43B PEG -1.58 EPS past 5Y -10.00% 200D Avg Chg -
Dividend 5.00% Price/Book 0.60 EPS next 5Y -2.70% 52W High Chg -16.00%
Recommedations 2.90 Quick Ratio 0.71 Shares Outstanding 1.19B 52W Low Chg 24.00%
Insider Own 0.35% ROA 2.79% Shares Float 1.18B Beta 1.14
Inst Own 83.41% ROE 0.26% Shares Shorted/Prior 38.48M/40.84M Price 10.43
Gross Margin 43.64% Profit Margin 0.36% Avg. Volume 9,555,456 Target Price 15.00
Oper. Margin 13.68% Earnings Date May 6 Volume 8,361,564 Change 2.05%
About Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc. News
03/27/24 Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
03/14/24 Is Viatris a Great Dividend Stock or Just a Value Trap?
03/11/24 2 Dirt Cheap Dividend Stocks to Buy and Hold
03/11/24 UPDATE 2-US FDA declines to approve Viatris's injection for multiple sclerosis
03/08/24 Viatris Inc's Dividend Analysis
03/05/24 Insider Sell: President of Greater China Xiangyang Ni Sells 21,532 Shares of Viatris Inc (VTRS)
03/05/24 Viatris Inc. (NASDAQ:VTRS) Q4 2023 Earnings Call Transcript
03/05/24 13 Best Pharma Dividend Stocks To Buy in 2024
03/04/24 Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
02/28/24 Q4 2023 Viatris Inc Earnings Call
02/28/24 Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
02/28/24 Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
02/28/24 Viatris forecasts strong 2024 sales on higher demand for branded drugs
02/28/24 Viatris Inc (VTRS) Meets 2023 Financial Targets and Sets Course for Continued Growth in 2024
02/28/24 Viatris pays $350M to gain two drugs from Idorsia
02/28/24 Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
02/28/24 Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
02/27/24 3 Overextended Stocks That Need to Slash Their Dividends ASAP
02/27/24 Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
02/23/24 Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
VTRS Chatroom

User Image StockInvest_us Posted - 8 hours ago

Signal alert: $VTRS - Oversold Trend Short (Undervalued) https://stockinvest.us/l/pPT1YsGBxz

User Image Stock_Titan Posted - 1 day ago

$VTRS Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline https://www.stocktitan.net/news/VTRS/viatris-hosts-r-amp-d-event-focusing-on-its-collaboration-with-eaf0mllf3ids.html

User Image TraderJackson_ Posted - 2 days ago

$VTRS $REXR $CRK $JD BREAKING OUT šŸƒ

User Image TickrTalk0007 Posted - 3 days ago

$VTRS anyone know why the Head of Eyecare Jeff Nau was not on the earnings call? it seemed odd $OCUP

User Image PupzInvestor Posted - 6 days ago

$VTRS Has not seen past 16 dollars a share since May of 2021. It's good to collect dividends though.

User Image scottcod Posted - 1 week ago

$VTRS Just do it šŸš€

User Image Bankpas Posted - 1 week ago

$VTRS they bought in on 2 big phase 3 studies @Idorsia pharma for 350 million $ā€¦.winners in the long run!

User Image lifeisatrade Posted - 1 week ago

Here are the cheapest stocks in the S&P 500 on your playlist: 1. $UAL (United Airlines Holdings Inc.) 2. $VTRS (Viatris Inc.) 3. $APA (APA Corporation) 4. $WBA (Walgreens Boots Alliance Inc.) These stocks could present potential opportunities.

User Image insiderbuyingselling Posted - 1 week ago

$VTRS new insider selling: 250000 shares. http://insiderbuyingselling.com/?t=VTRS

User Image Wolf0fBanta Posted - 1 week ago

$VTRS great value, long term play + solid dividends in the meantime

User Image Ran33 Posted - 2 weeks ago

$VTRS Poor VTRS shareholders probably thought they were heading places.

User Image RoundBall54 Posted - 2 weeks ago

$OCUP For those new to OCUP here's a recap. (Do your own DD). The licensing deal between Ocuphire Pharma, Inc. ($OCUP) and Viatris Inc. ($VTRS) involves the approval of RYZUMVIā„¢ (phentolamine ophthalmic solution) 0.75% by the U.S. Food and Drug Administration (FDA). RYZUMVIā„¢ has been approved for the treatment of pharmacologically induced mydriasis (pupil dilation) caused by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide). Expected to be commercially available in the U.S. during the first half of 2024. Viatris made an upfront cash payment of $35 million to Ocuphire as well as a $10m milestone payment on FDA approval of Nyxol (now known as RYZUMVI). Ocuphire to receive additional regulatory milestone payments upon approval of presbyopia and night vision disturbances indications. Ocuphire will receive double digit royalties on worldwide net sales of RYZUMVIā„¢. The agreement extends until 2040.

User Image Skywalkerblack Posted - 2 weeks ago

$VTRS hoping for a surprise buyout

User Image Herbicheck Posted - 2 weeks ago

$VTRS Iā€™m a buyer at 12.51

User Image DieHaendezumHimmel Posted - 2 weeks ago

$VTRS I got Jan 25 Calls strike 15 @ 0.49. I think it was a great buy

User Image ahab Posted - 2 weeks ago

$VTRS worst stock in the worst sector, let's make some money.

User Image HarveyToronto Posted - 2 weeks ago

$VTRS is planning to buy back $2B shares. (more than 10% of total shares) This is a supercheap value stock that all the bad news are already priced in.

User Image BoeingStingray Posted - 2 weeks ago

$VTRS doesnā€™t affect anything. Bullish. FDA is not approving anything MS related.

User Image ElijahJobs Posted - 2 weeks ago

$VTRS Looks like they already have more data to re-submit for approval. But other bigger potential blockbusters are in the pipeline. A very good value here. JMO https://finance.yahoo.com/news/1-us-fda-declines-approve-112415638.html

User Image CDMO Posted - 2 weeks ago

$VTRS Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the U.S. Food and Drug Administration (FDA). The Companies are reviewing the content of the CRL and will be determining the appropriate next steps. The Companies continue to believe in the potential of the product to provide an important new treatment advancement for patients with multiple sclerosis. The receipt of this CRL does not result in a change to Viatris' 2024 financial guidance or its new product revenue range of $450-550M.

User Image Novice1a Posted - 2 weeks ago

@BoeingStingray $OCUP $vtrs won approval for Ryzumvi back in September of last year. Viatris should be rolling out ryzumvi soon after this month's meeting.

User Image UnoffensiveName Posted - 2 weeks ago

$VTRS If it's a CRL why no announcement from Viatris?

User Image counttrarian Posted - 2 weeks ago

$VTRS Guidance remaining the same, which makes sense given that approval didn't seem to be baked into the numbers. Disappointed for the patients. Company recently reported additional studies so maybe they'll repackage the application depending on the reasons cited. If it is due to safety that would be easier than efficacy etc.

User Image counttrarian Posted - 2 weeks ago

$VTRS Looks like a CRL, very unexpected.

User Image Novice1a Posted - 2 weeks ago

$OCUP it's all making since now why $vtrs was getting all the glory for the FDA approval of Ryzumvi. They paid hundreds of millions on this molecule as part of the FAMY deal. Now they're going to pay tens of millions to launch Ryzumvi plus the 2 indicators in the pocket that works in correcting 2 other eye conditions. If you're in your forties no need for readers just reach for the eye drops for hours of reading pleasure. Lol. Repeat customers on a daily basis instead of just once a year treatment on the other 2 indicators. If they get approved Vtrs will be king. Rooting for Viatris. And not one more penny will OCUP have to pay for the royalties. APX3330 is just a bonus if passes SPA. The key "Big Pharma Viatris their team and resources".

User Image Novice1a Posted - 2 weeks ago

@Rush__2112 @JBResearch 150 million imo is the minimum we should see this year of Ryzumvi. $VTRS didn't invest hundreds of millions on this molecule for them to flop out of the starting gate. If anybody can promote this product it's them if not we're?

User Image BoeingStingray Posted - 2 weeks ago

$VTRS a PDUFA date is a ā€œbest estimateā€ as to when the FDA will act. Those speculating there is information that hasnā€™t been disclosed are flat wrong

User Image BoeingStingray Posted - 2 weeks ago

$vtrs Ocuphire and Viatris won approval Wednesday for Ryzumvi (phentolamine ophthalmic solution) for the reversal of pharmacologically-induced pupil dilation. While the topical drug does not come with a boxed warning, its label does carry warnings for uveitis and other common adverse effects of treatment, including site discomfort and conjunctival hyperemia. The partners intend to launch Ryzvumi in the U.S. in the first half of 2024. Artificial dilation can last from six to 24 hours, creating barriers for some patients. ā€œOur hope is that by addressing patient dilation barriers, we're empowering eye care professionals to broaden exam availability, leading to enhanced eye health outcomes,ā€ Viatris Eye Care division president Jeffrey Nau said in a prepared statement.

User Image BoeingStingray Posted - 2 weeks ago

Viatris Inc (VTRS) Meets 2023 Financial Targets and Sets Course for Continued Growth in 2024 $vtrs https://finance.yahoo.com/news/viatris-inc-vtrs-meets-2023-125222111.html

User Image counttrarian Posted - 2 weeks ago

$VTRS By now we can presume they have the decision by the NDA. If it was (an unexpected) CRL, then they will likely release a PR later tonight to try to lessen the negativity. If approval they may be waiting till Mon. AM when the great news (for patients and the companies involved alike) will have max impact.

Analyst Ratings
Piper Sandler Neutral Mar 28, 24
Piper Sandler Neutral Nov 22, 23
B of A Securities Underperform Oct 23, 23
Barclays Underweight Jun 23, 23
Barclays Equal-Weight Apr 25, 23
Barclays Equal-Weight Apr 24, 23
Barclays Overweight Feb 28, 23
BMO Capital Market Perform Feb 17, 23
Barclays Overweight Feb 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cuneo Andrew See Remarks See Remarks Jan 04 Sell 11.50 4,000 46,000 42,795 01/05/24
Cuneo Andrew See Remarks See Remarks Dec 14 Sell 10.50 4,000 42,000 46,795 12/15/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Sell 9.37 14,937 139,960 64,658 11/24/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Option 0 33,179 79,595 11/24/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Mar 02 Sell 11.13 6,241 69,462 46,416 03/06/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Mar 02 Option 0 15,600 49,564 03/06/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Feb 27 Sell 11.22 5,250 58,905 37,057 03/01/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Feb 27 Option 0 13,142 42,307 03/01/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Option 0 31,644 41,965 11/25/22
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Sell 10.95 12,800 140,160 29,165 11/25/22
van der Meer Mohr Pauline Director Director Aug 17 Sell 10.5839 9,440 99,912 20,543 08/19/22
Taddese Menassie See Remarks See Remarks May 27 Sell 12.0737 8,813 106,406 05/27/22
READ IAN C Director Director Mar 21 Option 0.00 166 14,497 03/23/22
PARRISH MARK W Director Director Mar 21 Option 0.00 166 82,250 03/23/22
MARK RICHARD A Director Director Mar 21 Option 0.00 166 33,165 03/23/22
Lyons Dillon JoEllen Director Director Mar 21 Option 0.00 166 39,546 03/23/22
DIMICK NEIL F Director Director Mar 21 Option 0.00 166 75,200 03/23/22
KORMAN HARRY Director Director Mar 21 Option 0.00 166 50,638 03/23/22
KILTS JAMES M Director Director Mar 21 Option 0.00 166 79,402 03/23/22
HIGGINS MELINA E Director Director Mar 21 Option 0.00 166 63,068 03/23/22
CORNWELL W DON Director Director Mar 21 Option 0.00 166 22,197 03/23/22
CORNWELL W DON Director Director Mar 15 Buy 9.8968 2,700 26,721 22,031 03/15/22
GOETTLER MICHAEL Chief Executive Offi.. Chief Executive Officer Mar 15 Buy 9.866 50,352 496,773 136,796 03/15/22
COURY ROBERT J Executive Chairman Executive Chairman Mar 09 Sell 10.17 500,000 5,085,000 03/11/22